Incidence and molecular epidemiology of hepatitis C virus reinfection in prisons in Catalonia, Spain (Re-HCV study).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 09 2023
25 09 2023
Historique:
received:
25
07
2023
accepted:
13
09
2023
medline:
27
9
2023
pubmed:
26
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Hepatitis C virus (HCV) reinfection may hamper HCV elimination in prisons. We aimed to (i) determine the reinfection rate in people treated for HCV in Catalan prisons, (ii) measure reinfection in people entering prisons, and (iii) characterize the molecular epidemiology of HCV in prisons and people who inject drugs (PWID) in the community. Re-HCV was a prospective study in eight prisons (2019-2020) including two groups: (1) people cured with treatment in prison and followed-up every 6 months, and (2) people testing HCV-RNA positive at incarceration. Bio-behavioral data were collected. HCV isolates were sequenced and phylogenetically analyzed with those of PWID in the community. Reinfection follow-up after treatment was achieved in 97 individuals (103.05 person-years). Two reinfections were detected, resulting in an incidence ≤ 10/100 person-years. Among people entering prison, 2% (359/17,732) were viremic, of which 334 (93.0%) were included, and 44 (13.5%) presented with reinfection (84.7% being PWID). Frequently, HCV isolates in prisons and PWID in the community were phylogenetically related. Although HCV reinfection is low after treatment, it is common in people entering Catalan prisons. To maintain a low HCV prevalence in prisons, harm-reduction services and test-and-treat programs for PWID should be strengthened both inside and outside prisons.
Identifiants
pubmed: 37749145
doi: 10.1038/s41598-023-42701-1
pii: 10.1038/s41598-023-42701-1
pmc: PMC10520040
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16012Investigateurs
Núria Teixidó
(N)
Anna Sastre
(A)
Ana Ruíz
(A)
Carlos Gallego
(C)
Carlos Touzón
(C)
Concepció Solé
(C)
Ramón Planella
(R)
Elisa Vaz
(E)
Rafael A Guerrero
(RA)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. Springer Nature Limited.
Références
Clin Infect Dis. 2022 Nov 14;75(10):1809-1819
pubmed: 35362522
Clin Infect Dis. 2016 Mar 15;62(6):683-694
pubmed: 26787172
BMC Public Health. 2019 Jan 8;19(1):30
pubmed: 30621658
Am J Gastroenterol. 2018 Nov;113(11):1639-1648
pubmed: 29946175
J Viral Hepat. 2018 Nov;25(11):1280-1286
pubmed: 29851225
Addiction. 2020 May;115(5):901-913
pubmed: 31633853
Int J Drug Policy. 2021 Apr;90:103057
pubmed: 33310634
Semergen. 2021 Jan-Feb;47(1):47-55
pubmed: 33358541
JHEP Rep. 2022 Sep 13;4(12):100580
pubmed: 36316992
Hepatology. 2021 Aug;74(2):591-606
pubmed: 33609288
J Hepatol. 2020 Apr;72(4):643-657
pubmed: 31785345
Int J Drug Policy. 2019 Oct;72:189-194
pubmed: 31160156
J Gastroenterol Hepatol. 2020 Sep;35(9):1570-1578
pubmed: 31957902
J Hepatol. 2023 Feb;78(2):452
pubmed: 36464532
Int J Drug Policy. 2020 Jun;80:102734
pubmed: 32470849
Hepatology. 2013 Oct;58(4):1215-24
pubmed: 23504650
J Viral Hepat. 2020 Apr;27(4):449-452
pubmed: 31749225
Drug Alcohol Depend. 2015 Feb 1;147:196-202
pubmed: 25496706
J R Soc Interface. 2015 Mar 6;12(104):20141197
pubmed: 25589564
Int J Drug Policy. 2019 Oct;72:181-188
pubmed: 31253391
J Hepatol. 2022 Mar;76(3):549-557
pubmed: 34634387
Int J Drug Policy. 2019 Dec;74:236-245
pubmed: 31706159
Rev Esp Sanid Penit. 2019;21(3):153-160
pubmed: 32083278